April 22, 2025CorporateTerumo unveils “Terumo Group Statement on Nature,” a guideline for its actions on conservation and restoration of natural environments
April 16, 2025CorporateTerumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerDaly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth
April 16, 2025CorporateTerumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort –
Top Management Message Message from top management to shareholders and investors. /investors/management/message Corporate Governance /about/governance Compliance /about/compliance Leadership Team /about/leadership Business Risks Major risks that may affect the business performance and financial position of the Terumo Group are described. /investors/management/risk IR Policy /investors/management/ir_policy Disclaimer /investors/disclaimer
